Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 178

Development of peptide vaccine for diffuse intrinsic pontine glioma Executive ...

Hypothesis- Our hypothesis is that a peptide vaccination targeting H3.3K27M will be an effective tumor-specific therapy for patients with gliomas expressing this mutation, without antigen escape or toxicity.    Goals- To identify an effective therapy that will prolong the survival of children with DIPG. We will pursue ...

Short-pulse ultrasound delivery of panobinostat for the treatment of diffuse ...

Children with diffuse intrinsic pontine gliomas (DIPGs) have a 2-year survival rate of less than 10%. Compared to other brain cancers, DIPG is particularly difficult to treat because it spreads behind an intact blood-brain barrier (BBB) affecting healthy developing paediatric brain tissue. There are currently no effective treatments for this disease. ...

Eliminating Therapy-Resistant Diffuse Intrinsic Pontine Gliomas with Oncolytic Picorna Virus ...

Diffuse intrinsic pontine glioma (DIPG) is the most lethal childhood cancer, and virtually all children with this disease die within 1-2 years of diagnosis. Major challenges for the development of new therapies include the lack of clinically relevant animal model system,difficulties of efficient drug delivery across the blood brain ...

COMBATT DMG: Combined anti-tumor targeting of diffuse midline gliomas

Paediatric high-grade glioma of the brainstem – diffuse midline glioma (DMG), represent the most aggressive primary tumor of the central nervous system (CNS) and are responsible for half of all brain cancer deaths in children. Recent scientific advances provide much needed insight into the biology of the disease – particularly ...

Dual targeting processive transcription for Myc-driven circuitry in medulloblastoma

Medulloblastomas (MB) are the most common brain cancer in children.  The highest-risk subgroups are defined by elevated expression of a protein called Myc (Myc-MB) and exhibit high rates of metastasis and disease recurrence, resulting in unacceptable long-term survival rates of less than 30%. The Myc protein itself has proven ...